MedTrace Logo

A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases.

NCT01884974 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2015-06-16

No results posted yet for this study

Summary

Pulmonary hypertension (PH) is defined as a group of diseases characterised by an elevated mean pulmonary artery pressure (Ppa) ≥25 mmHg at rest. Recently, chronic myeloproliferative diseases (CMPD) associated with pulmonary hypertension were included in the group 5 category, corresponding to PH for which the aetiology is unclear and/or multifactorial. CMPD include chronic myelogenous leukaemia, chronic neutrophilic leukaemia and chronic eosinophilic leukaemia (which primarily express a myeloid phenotype and polycythaemia vera), idiopathic myelofibrosis, and essential thrombocytosis in which erythroid or megakaryocytic hyperplasia predominates.

The purpose of this research:

1. Assess Prevalence of PH in patients with CMPD in Northern Israel
2. Describe the demographics and clinical course in patients with CMPD who are diagnosed with PH.

Conditions

  • Myeloproliferative Disease
  • Pulmonary Hypertension

Interventions

OTHER

myeloproliferative disease

Echocardiogram, demographic data, St George respiratory questioner

Sponsors & Collaborators

  • Carmel Medical Center

    lead OTHER

Principal Investigators

  • Shoshan Perek, MD · Carmel Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01884974 on ClinicalTrials.gov